In vitro activity of A-56268 (TE-031), a new macrolide, compared with that of erythromycin and clindamycin against selected gram-positive and gram-negative organisms.
AUTOR(ES)
Benson, C A
RESUMO
The in vitro activity of A-56268 was determined and compared with that of erythromycin and clindamycin against a limited spectrum of 401 gram-positive and gram-negative organisms. A-56268 was quite active against erythromycin-susceptible Staphylococcus aureus, Neisseria gonorrhoeae, Listeria monocytogenes, Streptococcus pneumoniae, Streptococcus pyogenes, and group B streptococci and was moderately active against Campylobacter fetus subsp. fetus. A-56268 was consistently bactericidal only for S. pneumoniae. The activity of A-56268 was comparable to that of erythromycin against most organisms tested.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=174717Documentos Relacionados
- In vitro activity of A-56268 (TE-031), a new macrolide antibiotic, compared with that of erythromycin and other antimicrobial agents.
- In vitro and in vivo evaluation of A-56268 (TE-031), a new macrolide.
- In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin.
- In vitro activity of ramoplanin against vancomycin-resistant gram-positive organisms.
- In vitro activity of biapenem against clinical isolates of gram-positive and gram-negative bacteria.